de Arriba AF - Search Results

1

Synthesis and SAR of a new series of COX-2-selective inhibitors: pyrazolo[1,5-a]pyrimidines.

Almansa C, de Arriba AF, Cavalcanti FL, Gómez LA, Miralles A, Merlos M, García-Rafanell J, Forn J. Almansa C, et al. Among authors: de arriba af. J Med Chem. 2001 Feb 1;44(3):350-61. doi: 10.1021/jm0009383. J Med Chem. 2001. PMID: 11462976

2

Synthesis and structure-activity relationship of a new series of COX-2 selective inhibitors: 1,5-diarylimidazoles.

Almansa C, Alfón J, de Arriba AF, Cavalcanti FL, Escamilla I, Gómez LA, Miralles A, Soliva R, Bartrolí J, Carceller E, Merlos M, García-Rafanell J. Almansa C, et al. Among authors: de arriba af. J Med Chem. 2003 Jul 31;46(16):3463-75. doi: 10.1021/jm030765s. J Med Chem. 2003. PMID: 12877584

3

Diphenylpropionic acids as new AT1 selective angiotensin II antagonists.

Almansa C, Gómez LA, Cavalcanti FL, de Arriba AF, Rodríguez R, Carceller E, García-Rafanell J, Forn J. Almansa C, et al. Among authors: de arriba af. J Med Chem. 1996 May 24;39(11):2197-206. doi: 10.1021/jm9508853. J Med Chem. 1996. PMID: 8667363

4

Synthesis and structure-activity relationship of a new series of potent AT1 selective angiotensin II receptor antagonists: 5-(biphenyl-4-ylmethyl)pyrazoles.

Almansa C, Gómez LA, Cavalcanti FL, de Arriba AF, García-Rafanell J, Forn J. Almansa C, et al. Among authors: de arriba af. J Med Chem. 1997 Feb 14;40(4):547-58. doi: 10.1021/jm9604383. J Med Chem. 1997. PMID: 9046346

5

In vitro pharmacological characterization of a new selective angiotensin AT1 receptor antagonist, UR-7280.

De Arriba AF, Gómez-Casajús LA, Cavalcanti F, Almansa C, García-Rafanell J, Forn J. De Arriba AF, et al. Eur J Pharmacol. 1996 Dec 30;318(2-3):341-7. doi: 10.1016/s0014-2999(96)00794-7. Eur J Pharmacol. 1996. PMID: 9016924

6

Effect of 4-trifluoromethyl derivatives of salicylate on nuclear factor kappaB-dependent transcription in human astrocytoma cells.

Hernández M, de Arriba AF, Merlos M, Fuentes L, Crespo MS, Nieto ML. Hernández M, et al. Among authors: de arriba af. Br J Pharmacol. 2001 Jan;132(2):547-55. doi: 10.1038/sj.bjp.0703820. Br J Pharmacol. 2001. PMID: 11159705 Free PMC article.

7

Inhibition of cardiac hypertrophy by triflusal (4-trifluoromethyl derivative of salicylate) and its active metabolite.

Planavila A, Rodríguez-Calvo R, de Arriba AF, Sánchez RM, Laguna JC, Merlos M, Vazquez-Carrera M. Planavila A, et al. Among authors: de arriba af. Mol Pharmacol. 2006 Apr;69(4):1174-81. doi: 10.1124/mol.105.016345. Epub 2006 Jan 18. Mol Pharmacol. 2006. PMID: 16421291

8

UR-1505, a new salicylate, blocks T cell activation through nuclear factor of activated T cells.

Román J, de Arriba AF, Barrón S, Michelena P, Giral M, Merlos M, Bailón E, Comalada M, Gálvez J, Zarzuelo A, Ramis I. Román J, et al. Among authors: de arriba af. Mol Pharmacol. 2007 Aug;72(2):269-79. doi: 10.1124/mol.107.035212. Epub 2007 May 2. Mol Pharmacol. 2007. PMID: 17475810

9

Synthesis of a chiral artificial receptor with catalytic activity in Michael additions and its chiral resolution by a new methodology.

Simón L, Muñiz FM, de Arriba AF, Alcázar V, Raposo C, Morán JR. Simón L, et al. Among authors: de arriba af. Org Biomol Chem. 2010 Apr 21;8(8):1763-8. doi: 10.1039/b925367j. Org Biomol Chem. 2010. PMID: 20449475

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

9 results

Search Page

Filters